What the FDA Pharmacy Compounding Advisory Committee’s July 2026 Peptide Meeting Means for Patients and Providers

Peptides have become one of the most talked-about topics in health and wellness. Patients ask about them. Providers field questions about them. And this month, a federal advisory committee is meeting to decide whether several popular peptides should be added to the list of bulk substances that licensed pharmacies can legally compound.

Here is a look at what is happening, why it matters, and what patients and providers should keep in mind.

What is the PCAC, and why is it meeting?

The Pharmacy Compounding Advisory Committee (PCAC) is a group of outside experts that advises the FDA on compounding rules. The FDA asks the committee to review specific bulk drug substances and recommend whether they should be added to, or kept off, the Section 503A Bulk Drug Substances List. That list determines which active pharmaceutical ingredients (API) a 503A compounding pharmacy may use to prepare a patient-specific prescription (FDA, Pharmacy Compounding Advisory Committee).

The PCAC will meet on July 23-24, 2026, at the FDA’s White Oak campus in Maryland. Over these two days, the PCAC will review seven peptides: BPC-157, KPV, TB-500, and MOTS-c on the first day, and emideltide (also called DSIP), semax, and epitalon on the second (FDA meeting notice, July 23-24, 2026).

In April 2026, the FDA removed these seven peptides, along with several others, from Category 2 of the Bulks List, a designation that had barred compounding pharmacies from using them since 2023. Coming off Category 2 does not mean a peptide can be compounded. It means the substance is now eligible for the FDA’s review process, which includes the PCAC meeting.

What patients need to know

1. This is a review, not an approval. PCAC’s job is to thoughtfully review the information provided by regulatory, industry, clinical, and patient stakeholders, then make a recommendation for or against inclusion on the Bulks List. The FDA makes the final decision whether to adopt a recommendation from the PCAC. There is no defined timeframe for the FDA to respond to the PCAC recommendation.
2. None of these peptides are FDA-approved drugs. Inclusion on the 503A Bulks List will allow licensed pharmacies to compound the bulk peptide substances under a valid prescription for a specific patient. It does not mean the FDA has approved them as safe and effective treatment for any specific condition or disease.
3. Where a peptide comes from matters. A compounded medication from a licensed 503A pharmacy is made with an active pharmaceutical ingredient obtained from an FDA-registered supplier and prepared by a licensed pharmacist pursuant to a valid prescription from a licensed health care provider for a specific patient, all within a facility inspected by state and federal regulatory agencies to ensure quality standards are maintained. Such assurances do not exist if peptides are obtained outside the regulated healthcare system.
4. Talk to a prescriber first. If a patient is interested in peptide therapy, the safest starting point is a conversation with a provider who can evaluate whether it fits their specific health history, personal needs, and goals.

What providers need to know

Provider questions about peptides are not going away, no matter the outcome of the PCAC meeting. A few things are worth keeping in mind heading into the meeting and after it:

1. The evidence base is still developing. The peptides under review are being considered for clinical indications that range from wound healing to insomnia, and most have limited human clinical data behind them. FDA scientists reviewing the same substances have flagged gaps in the safety and efficacy evidence (NPR, June 30, 2026).
2. Approval under 503A would not extend to 503B. So far, the FDA has not indicated it will review these peptides for the 503B outsourcing facility Bulks List, which supports office-based and clinic dispensing at broader scale. 503B Bulks List approval is a separate process.
3. Sourcing and testing still matter most. Regardless of the outcome, patients will keep asking providers where a peptide comes from and how it is tested. Partnering with a pharmacy that verifies ingredients through FDA-registered suppliers and tests every batch for sterility, potency, and purity gives providers a straightforward answer.

What happens next with peptides

The PCAC  meeting will not settle the peptide question overnight. It is one step in a longer regulatory process, and the outcome for each peptide could differ. The PCAC meeting  does confirm  that peptide access is being actively debated at the federal level, and that patients and providers need reliable information now, not just after a final rule is published.

Empower operates both a 503A compounding pharmacy and a 503B outsourcing facility. Its API are sourced through qualified, FDA-registered suppliers, and every compounded batch is tested before it reaches a patient. As the PCAC review moves forward, Empower’s Medical Affairs team will continue tracking developments and sharing what they mean for prescribers and the patients they serve.

Frequently asked questions

Is peptide therapy legal right now?

It depends on the specific peptide. Some peptides already have a legal compounding pathway. The seven peptides under PCAC review this month do not yet have one; they are being evaluated for eligibility.

Does this meeting decide whether these peptides can be compounded?

No. The PCAC makes a recommendation. The FDA ultimately decides whether the peptides can be compounded.